IDYA Stock — IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. (IDYA)

Updated October 16, 2026.

IDYA is a Stock. Total return is 193.6% over the past 7.4 years, 8.2 points behind SPY at 201.8%.

IDEAYA Biosciences is a precision medicine oncology company developing targeted cancer therapeutics selected through molecular diagnostics, with a pipeline including Darovasertib for uveal melanoma, IDE849 for small cell lung cancer, and multiple other drug candidates in clinical trials, supported by strategic partnerships with major pharmaceutical companies including GlaxoSmithKline, Pfizer, and Roche. The company does not currently distribute to shareholders. This security appeals to growth-oriented investors seeking exposure to early-stage oncology drug development.

IDYA performance versus SPY

Price and return data through 2026-10-16.

Total return is 193.6% over the past 7.4 years, 8.2 points behind SPY at 201.8%. Over the past year its total return — price change plus distributions reinvested — is 18.6%. Its deepest 1-year drawdown was 27.1%.

IDYA key facts

Asset type

Stock

Asset class

Equity

Inception date

05/23/2019

Distribution frequency

None

Last close

$32.85 (as of 2026-10-16)

Market cap

$3,169,679,549

Average volume

655113.0

Beta

-0.039

Payout ratio

0.0%

Forward P/E

4.649

EPS

$-1.92

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IDYA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 27.1%.

Who may consider IDYA — and who may not

It is a weaker fit for investors who need monthly cash flow (IDYA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IDYA

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions